MSACL 2017 US Abstract

Bio: Before coming to ASU in 2013, Dr. Nedelkov spent 14 years at Intrinsic Bioprobes leading research and development in the field of proteomics and protein biomarkers. Prior to joining Intrinsic Bioprobes in 1999, Dr. Nedelkov was Postdoctoral Associate at Yale University, in the Department of Molecular Biophysics and Biochemistry. Dr. Nedelkov received his Ph.D. in Chemistry and Biochemistry from Arizona State University in 1997. Dr. Nedelkov has authored over 90 peer reviewed scientific articles, edited a book on New and Emerging Proteomics Techniques, presented at over 60 scientific meetings, and has 4 issued patents and several pending patent applications.

The last decade has seen increased efforts to bring MS-based protein tests into clinical labs; however, only a dozen such tests have been adopted thus far. Even when MS approaches result in new protein biomarkers discovery, enzymatic immunoassays oftentimes replace MS in clinical lab tests. One way to drive translation and adoption of MS protein tests is to target protein features that could only be detected with MS - such as post-translational modifications (PTMs) – thus generating both content and demand. Discussed in this presentation will be some viable PTM protein targets and the path forward for these clinical MS protein tests.

Long Abstract

The last decade has seen increased efforts to bring MS-based protein tests into clinical labs; however, only a dozen such tests have been adopted thus far. Even when MS approaches result in new protein biomarkers discovery, enzymatic immunoassays oftentimes replace MS in clinical lab tests. One way to drive translation and adoption of MS protein tests is to target protein features that could only be detected with MS - such as post-translational modifications (PTMs) – thus generating both content and demand. Discussed in this presentation will be some viable PTM protein targets and the path forward for these clinical MS protein tests.

References & Acknowledgements:

Financial Disclosure

Description

Y/N

Source

Grants

no

Salary

no

Board Member

no

Stock

no

Expenses

no

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above: